公司資料
Immutep Limited 股價、新聞與催化劑
- 股票代碼:
- IMMP
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Australia and listed in the U
股票表現
0.39 USD (+1.71%)
收盤價
最後更新: 2026年8月17日
61.3M USD
市值
股價為何變動
As of Aug 17, 2026, IMMP closed up 1.71% at $0.3865. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.
所在地與產業分類
Immutep is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.
商業模式特徵
The company depends on clinical readouts, translational validation, and the ability to maintain a narrow immunotherapy pipeline. Investors usually watch efficacy signals and strategic collaborations.
生技產業定位
Immutep occupies a specialized immuno-oncology niche within biotech. The stock is catalyst-sensitive because the platform still needs to prove broad clinical relevance.
未來催化劑
- Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment. The company still needs human proof.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。